Scarica l'app Stockscreener
17.37
1.76%
0.30
Pre-mercato:
17.65
0.28
+1.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech
H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada
AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan
AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView
Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - The Manila Times
Aktis Oncology Announces FDA Clearance of Investigational - GlobeNewswire
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - biospace.com
This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
AKTS (Aktis Oncology) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P TMI Index - MarketScreener
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Value Benchmark - marketscreener.com
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Huge insider buying now at this insurance giant and 2 biotechs - msn.com
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Innovative radiopharmaceutical platform targets major cancer types, backed by strong pipeline and funding - TradingView
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm
Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - Reuters
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
IPO Tracker 2026: Generate’s IPO Could Reach $425M, Largest Raise Yet - BioSpace
FDA OKs Fast Track to AKY-1189 in Metastatic Urothelial Cancer - Cure Today
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters
Ken Herrmann Net Worth (2026) - GuruFocus
US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):